Abstract
Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.
Keywords: Anti-HER2 therapy, breast cancer, HER-2/neu, elderly.
Graphical Abstract
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Andrographolide and its Analogs: Botanical Sources, Phytochemistry, Pharmacology, and Biotechnology
Novel Drug Delivery Systems (Part 2)
AI Innovations in Drug Delivery and Pharmaceutical Sciences; Advancing Therapy through Technology
Anthocyanins: Pharmacology and Nutraceutical Importance
Computer-Aided Drug Discovery Methods: A Brief Introduction
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Nanotechnology in Drug Discovery
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
82
